Abstract
The authors report a pilot open-label two-center therapeutic trial of oxatomide in 14 steroid-naive DMD boys aged 5-10 years. Comparison of linear evolutions between 3 months medication-free lead-in periods and 6 months treatment periods showed no significant differences in quantitative (QMT) and manual (MMT) measurements of muscle strength and timed functional tests. A modest mitigation of strength deterioration over time cannot be excluded.
Original language | English (US) |
---|---|
Pages (from-to) | 337-340 |
Number of pages | 4 |
Journal | European Journal of Paediatric Neurology |
Volume | 11 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2007 |
Externally published | Yes |
Keywords
- Clinical trial
- Duchenne
- Muscle
- Muscular dystrophy
- Oxatomide
- Treatment
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Clinical Neurology